Literature DB >> 1939146

Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2.

S Kumar1, C Baglioni.   

Abstract

Pretreatment of HT-1080 fibrosarcoma cells with tumor necrosis factor (TNF) induced resistance to the cytolytic activity of this cytokine in combination with cycloheximide. This resistance correlated with the synthesis of plasminogen activator inhibitor type-2 (PAI-2). HT-1080 cells were transfected with a PAI-2 expression vector in both sense and antisense orientation. The resistance to TNF-mediated cytolysis of transfected cell clones was correlated with the level of PAI-2 expression. Cells expressing antisense PAI-2 RNA showed reduced expression of PAI-2 and increased sensitivity to TNF-mediated cytolysis. Cells expressing constitutively PAI-2 were treated with TNF and cycloheximide to select cells with increased resistance to cytolysis and enhanced PAI-2 expression. PAI-2 gradually disappeared during a treatment with TNF and cycloheximide. This finding suggested that PAI-2 formed a complex with a target proteinase, which could be involved in mediating the cytolytic activity of TNF.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1939146

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival.

Authors:  K M Dougherty; J M Pearson; A Y Yang; R J Westrick; M S Baker; D Ginsburg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

2.  SerpinB2 mediated regulation of macrophage function during enteric infection.

Authors:  Terez Shea-Donohue; Aiping Zhao; Toni M Antalis
Journal:  Gut Microbes       Date:  2014-02-05

3.  A redox-sensitive loop regulates plasminogen activator inhibitor type 2 (PAI-2) polymerization.

Authors:  Malgorzata Wilczynska; Sergei Lobov; Per-Ingvar Ohlsson; Tor Ny
Journal:  EMBO J       Date:  2003-04-15       Impact factor: 11.598

4.  Expression of interleukin 1-inducible genes and production of interleukin 1 by aging human fibroblasts.

Authors:  S Kumar; A J Millis; C Baglioni
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

5.  TANK-binding kinase 1 (TBK1) controls cell survival through PAI-2/serpinB2 and transglutaminase 2.

Authors:  Mireille Delhase; Soo-Youl Kim; Ho Lee; Aya Naiki-Ito; Yi Chen; Eu-Ree Ahn; Kazuhiro Murata; Se-Jin Kim; Norman Lautsch; Koichi S Kobayashi; Tomoyuki Shirai; Michael Karin; Makoto Nakanishi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-27       Impact factor: 11.205

6.  Nucleotide variations in genes encoding plasminogen activator inhibitor-2 and serine proteinase inhibitor B10 associated with prostate cancer.

Authors:  Go Shioji; Yoichi Ezura; Toshiaki Nakajima; Kenji Ohgaki; Hiromichi Fujiwara; Yoshinobu Kubota; Tomohiko Ichikawa; Katsuki Inoue; Taro Shuin; Tomonori Habuchi; Osamu Ogawa; Taiji Nishimura; Mitsuru Emi
Journal:  J Hum Genet       Date:  2005-09-20       Impact factor: 3.172

7.  Protease inhibitors selectively block T cell receptor-triggered programmed cell death in a murine T cell hybridoma and activated peripheral T cells.

Authors:  A Sarin; D H Adams; P A Henkart
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

8.  A mesangium-predominant gene, megsin, is a new serpin upregulated in IgA nephropathy.

Authors:  T Miyata; M Nangaku; D Suzuki; R Inagi; K Uragami; H Sakai; K Okubo; K Kurokawa
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

9.  Cyclin D3 sensitizes tumor cells to tumor necrosis factor-induced, c-Myc-dependent apoptosis.

Authors:  R U Jänicke; X Y Lin; F H Lee; A G Porter
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

10.  Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas.

Authors:  Salvatore Ulisse; Enke Baldini; Marcella Mottolese; Steno Sentinelli; Patrizia Gargiulo; Brancato Valentina; Salvatore Sorrenti; Anna Di Benedetto; Enrico De Antoni; Massimino D'Armiento
Journal:  BMC Cancer       Date:  2010-04-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.